Provided by Tiger Fintech (Singapore) Pte. Ltd.

Acumen Pharmaceuticals, Inc.

1.00
-0.0600-5.66%
Volume:95.43K
Turnover:99.28K
Market Cap:60.57M
PE:-0.59
High:1.13
Open:1.09
Low:1.00
Close:1.06
Loading ...

Acumen Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
12 Nov 2024

Acumen Pharmaceuticals Q3 2024 GAAP EPS $(0.50) Misses $(0.36) Estimate

Benzinga
·
12 Nov 2024

BRIEF-Acumen Pharmaceuticals, Inc. Q3 Income From Operations USD -32.265 Million

Reuters
·
12 Nov 2024

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire
·
12 Nov 2024

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

GlobeNewswire
·
12 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Nov 2024

Acumen Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 Nov 2024

BRIEF-Acumen Pharmaceuticals Appoints Amy Schacterle As Chief Regulatory Officer & Head Of Quality

Reuters
·
06 Nov 2024

Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality

TIPRANKS
·
06 Nov 2024

Acumen Pharmaceuticals Appoints DR. Amy Schacterle as Chief Regulatory Officer & Head of Quality

THOMSON REUTERS
·
06 Nov 2024

Press Release: Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

Dow Jones
·
06 Nov 2024

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

GlobeNewswire
·
06 Nov 2024

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing Ptau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17TH Annual Clinical Trials on Alzheimer’s Disease Conference

THOMSON REUTERS
·
31 Oct 2024

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

GlobeNewswire
·
31 Oct 2024